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Treatment outcomes among patients treated for multidrug-resistant tuberculosis (MDR-TB)
are often sub-optimal. Therefore, the early prediction of poor treatment outcomes may be
useful in patient care, especially for clinicians when they have the ability to make treatment
decisions or offer counselling or additional support to patients. The aim of this study was to
develop a simple clinical risk score to predict poor treatment outcomes in patients with
MDR-TB, using routinely collected data from two large countries in geographically distinct
regions.
Methods
We used MDR-TB data collected from Hunan Chest Hospital, China and Gondar University
Hospital, Ethiopia. The data were divided into derivation (n = 343; 60%) and validation
groups (n = 227; 40%). A poor treatment outcome was defined as treatment failure, lost to
follow up or death. A risk score for poor treatment outcomes was derived using a Cox pro-
portional hazard model in the derivation group. The model was then validated in the valida-
tion group.
Results
The overall rate of poor treatment outcome was 39.5% (n = 225); 37.9% (n = 86) in the deri-
vation group and 40.5% (n = 139) in the validation group. Three variables were identified as
predictors of poor treatment outcomes, and each was assigned a number of points propor-
tional to its regression coefficient. These predictors and their points were: 1) history of taking
second-line TB treatment (2 points), 2) resistance to any fluoroquinolones (3 points), and 3)
smear did not convert from positive to negative at two months (4 points). We summed these
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points to calculate the risk score for each patient; three risk groups were defined: low risk (0
to 2 points), medium risk (3 to 5 points), and high risk (6 to 9 points). In the derivation group,
poor treatment outcomes were reported for these three groups as 14%, 27%, and 71%,
respectively. The area under the receiver operating characteristic curve for the point system
in the derivation group was 0.69 (95% CI 0.60 to 0.77) and was similar to that in the valida-
tion group (0.67; 95% CI 0.56 to 0.78; p = 0.82).
Conclusion
History of second-line TB treatment, resistance to any fluoroquinolones, and smear non-
conversion at two months can be used to estimate the risk of poor treatment outcome in
patients with MDR-TB with a moderate degree of accuracy (AUROC = 0.69).
Introduction
Multidrug-resistant tuberculosis (MDR-TB) is an emerging public health problem that
affected an estimated 457 000 people in 2017 [1]. The treatment of MDR-TB is lengthy (nine
to 24 months), complicated by potentially severe adverse effects, and is more costly than treat-
ment of drug susceptible tuberculosis (TB) [2, 3]. In addition, treatment outcomes are sub-
optimal [4–6], with only 54% of MDR-TB patients successfully treated globally [7]. A range of
clinical and demographic factors have been shown to be associated with poor treatment out-
comes, including drug resistance pattern, history of TB treatment, and smear result at the com-
mencement of treatment [5, 6, 8–13]. Developing a clinical risk score using readily available
predictors to identify individuals at increased risk of poor treatment outcomes could be a use-
ful aid in clinical decision making. Risk scores have been developed to predict the risk of TB
treatment outcomes (for drug susceptible TB) [14], severe dengue [15], coronary heart disease
[16, 17], paediatric mortality [18], and pulmonary embolism [19]. However, risk scores have
not yet been developed to predict treatment outcomes among patients with MDR-TB. There-
fore, the aim of this study was to develop a clinical risk score to predict the risk of poor treat-
ment outcome (i.e. treatment failure, lost to follow up or death) in patients with MDR-TB,
using routinely collected data from two large countries that have a high MDR-TB burden and
are geographically, economically and epidemiologically distinct.
Methods
Study design and settings
We conducted a retrospective cohort study using data collected from the MDR-TB treatment
centres at Gondar University Hospital, Ethiopia, and Hunan Chest Hospital, China. According
to the World Bank classification, Ethiopia is categorized as a low-income country, whereas
China is categorized as an upper-middle-income country [20]. However, both countries are
categorized by World Health Organization (WHO) as high TB and MDR-TB burden countries
[21]. Hunan Chest Hospital is located in Changsha, the capital city of Hunan province, and
Gondar University Hospital is located in northwest Ethiopia. The Hunan Chest Hospital and
the Gondar University Hospital established MDR-TB treatment centers in 2011 and 2010,
respectively. These hospitals provide comprehensive diagnostic and treatment services for all
people with presumptive drug resistant TB who live in their catchment area.
A risk score for prediction of MDR-TB treatment outcomes
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MDR-TB diagnosis
At Gondar University Hospital, from patients suspected of having DR-TB, sputum specimens
are sent to the national or regional laboratory for culture, and drug resistance is determined by
a line probe assay, Xpert1MTB/RIF or conventional drug susceptibility testing (DST);
whereas at the Hunan Chest Hospital, culture and DST are performed in the hospital’s labora-
tory. In addition, sputum specimens from all culture-positive TB patients from throughout the
province are referred to the Hunan Chest Hospital for DST. In the hospital, phenotypic DST
based on solid and liquid culture techniques, and molecular methods using line probe assays
as well as Xpert1MTB/RIF are performed. Both in Hunan Chest Hospital and Gondar Uni-
versity Hospital, smear microscopy with Ziehl-Neelsen staining and fluorescence microscopy
are used for the diagnosis and monitoring of TB.
MDR-TB treatment
At Hunan Chest Hospital, patients with MDR-TB are treated with an individualized treatment
regimen containing at least four drugs, based on their DST results and history of previous TB
treatment. The regimen usually includes an injectable agent (i.e. Kanamycin, Amikacin or
Capreomycin), a Fluoroquinolone (i.e. Levofloxacin, Ofloxacin or Moxifloxacin), Para-amino-
salicylic acid, Prothionamide, Pyrazinamide, Clarithromycin, Ethambutol, or Cycloserine. The
duration of treatment is approximately 24 months; and the injectable drugs are used for a min-
imum of six months. Patients are admitted to the hospital for one to two months during the
intensive phase and, while hospitalised, receive directly observed therapy (DOT) by trained
medical staff. During this time, patients also receive psychological support and counselling
from hospital nurses. When the patients are medically fit, they are treated as out-patients.
They receive support from trained family members or from trained supervisors in the commu-
nity and return to the hospital once a month for a drug refill. As part of routine care, sputum
microscopy and cultures are performed monthly for the first six months, and thereafter every
other month until the end of treatment.
At Gondar University Hospital, MDR-TB patients receive a standardized regimen of first
and second line TB drugs that consists of an eight-month intensive phase with a combination
of Pyrazinamide, Capreomycin, Levofloxacin, Prothionamide or Ethionamide and Cycloser-
ine, a twelve-month continuation phase with a combination of Pyrazinamide, Levofloxacin,
Prothionamide or Ethionamide, and Cycloserine [22]. However, certain groups of MDR-TB
patients cannot receive the standardized regimen. These groups include: pregnant women,
children, patients with co-morbidities such as chronic renal dysfunction, HIV or liver disease,
patients who report household contact with other rifampicin resistant (RR) or MDR-TB
patients, and patients who have a history of prior exposure to second-line TB drugs [22].
These group of patients require either a modification of the regimen or dose adjustment [22].
Data source
This study included all patients who were diagnosed with MDR- TB in Hunan Chest Hospital
from 2011–2014, and in Gondar University Hospital from 2010–2014. Patients who did not
start MDR-TB treatment and patients whose treatment result were not recorded were excluded
from the study. Demographic variables such as age, sex and occupation, and clinical variables
such as history of second-line TB treatment, resistance to ethambutol, resistance to injectable
TB drugs, resistance to fluoroquinolones, culture and smear results (at baseline and at follow
up), and treatment outcomes were obtained from the patients’ medical records (S1 File). To
develop and validate the risk score, the data obtained from the two hospitals were merged
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together, and divided into a derivation group (60%) and validation group (40%) using a ran-
dom number generator in STATA version 15 [23].
Definitions
Multidrug-resistant TB was defined as TB that is resistant to at least isoniazid and rifampicin
[24]. A poor treatment outcome was defined as the sum of the treatment outcomes: treatment
failure, lost to follow up or death. Treatment failure was defined as treatment terminated or a
need for permanent regimen change of at least two TB drugs due to an adverse drug reaction,
or lack of culture conversion by the end of the intensive phase, or bacteriological reversion in
the continuation phase after conversion to negative after the intensive phase, or evidence of
additional acquired resistance to fluoroquinolones or second-line injectable drugs [24, 25].
Lost to follow-up was defined as a patient whose treatment was interrupted for two consecu-
tive months or more [24, 25]. Death was defined as patients who died for any reason during
the course of treatment [24, 25]. Culture conversion (from positive to negative) was defined as
two consecutive negative sputum cultures taken at least 30 days apart following an initial posi-
tive culture [25]. Similarly, smear conversion (from positive to negative) was defined as two
consecutive negative sputum smears taken at least 30 days apart following an initial positive
sputum smear [25].
Statistical analysis
Categorical variables were presented as numbers and percentages, and continuous variables
were presented as means and standard deviations. The rate of poor treatment outcome was cal-
culated as the proportion of patients who had treatment failure lost to follow up or death dur-
ing the follow-up period among those who had started MDR-TB treatment.
The risk score was developed from the derivation group, using previously established
method [26]. We first performed univariable cox-proportional hazard models using demo-
graphic and clinical variables. We selected variables which had a p value <0.2 in the univari-
able analysis and checked for the presence of collinearity between the selected variables, using
Pearson’s correlation coefficient. A stepwise multivariable cox-proportional hazard model was
used to select the independent predictors (with a p-value <0.05), and to estimate their regres-
sion coefficients (β). Since the Pearson’s correlation coefficient showed that smear and culture
conversion status were correlated, we selected smear conversion and removed culture conver-
sion from the model. As a sensitivity analysis, we run two different models that contain culture
conversion and smear conversion. Because these two models provided similar results, we pre-
ferred only the model that contain smear conversion. We selected smear conversion because it
is less expensive, widely available, and more convenient than culture conversion to predict the
treatment outcomes of patients at peripheral and lower-resource settings.
A score for each of the identified variables was calculated based on their regression coeffi-
cients. The regression coefficients (β) for the selected risk factors were estimated from the mul-
tivariable Cox proportional hazards model. The score for these variables was calculated by
dividing the coefficient of the variable by the lowest β value in the model, multiplied by a con-
stant, and rounded to the nearest integer. The constant was determined based on the Framing-
ham study, in terms of the increase in risk of death and treatment failure associated with an
increase in age. The constant for our study model was set at two. A risk score was finally calcu-
lated for each patient by summing up the points of all risk factors, and the population was
divided into tertiles: patients at low risk, patients at medium risk, and patients at high risk for
poor treatment outcome.
A risk score for prediction of MDR-TB treatment outcomes
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To evaluate the performance of the scoring systems, we assessed the discrimination (i.e. the
ability of the scoring system to distinguish between patients with poor treatment outcomes
and patients with successful treatment outcomes) and calibration (i.e. the level of agreement
between predicted probabilities and observed outcomes) power of the score.
The receiver operating characteristic curve (ROC) was plotted and the area under the curve
(AUC) was calculated to measure and compare the discriminatory power of the scoring system
in the derivation and validation group. The 95% CI for the ROC curve was calculated by
STAT, using “diagt” command.
The expected number of poor treatment outcome as predicted by the scoring system was
compared with the observed number of poor treatment outcome in each group. A value of
P> 0.05 was accepted as good calibration. Calibration was shown graphically by plotting the
observed and predicted poor treatment outcomes, grouped according to quartile of predicted
probabilities. All the analyses were performed using Stata Statistical Software: Release 14.0
(College Station, TX: Stata Corporation LP).
Ethics approval and consent to participate
Ethics approval was obtained from the Australian National University Human Research Ethics
Committee (protocol number 2016/218) and from the Institutional Review Board of the Uni-
versity of Gondar. Permission was granted to access the secondary data from Tuberculosis
Control Institute of Hunan Province, and this was documented in a letter. All data were fully
anonymized before we accessed them, and the study was conducted in collaboration with
researchers from Gondar University and Hunan Chest Hospital.
Results
Baseline characteristics
A total of 570 bacteriologically confirmed MDR-TB patients were included in the study (Fig
1). The baseline demographic and clinical characteristics of the patients are presented in
Table 1. Of 570 patients, 343 (60%) randomly selected patients were assigned in the deviation
group, and the remaining 227 (40%) patients were assigned in the validation group. The char-
acteristics of the study participants in Hunan Chest Hospital, China and University of Gondar,
Ethiopia are presented in Table 2.
Predictors of poor treatment outcomes
During the follow up period, the overall rate of poor treatment outcomes was 39.5% (n = 225);
37.9% (n = 86) in the derivation group and 40.5% (n = 139) in the validation group (Table 3).
Table 4 shows the crude hazard ratios from the univariable Cox proportional hazard model in
the derivation group in patients with MDR-TB. Variables with p-value less than 0.2 in the uni-
variable Cox proportional hazard model were selected for the multivariable Cox proportional
hazard model.
Risk score derivation and validation
In the final multivariable Cox proportional hazard model, three variables were identified as
independent predictors of poor treatment outcomes (with a p-value <0.05), and each was
assigned a number of points, proportional to its regression coefficient. These predictors and
their points were: 1) history of taking second-line TB treatment (2 points), 2) resistance to any
fluoroquinolones (3 points), and 3) smear did not convert from positive to negative at two
months (4 points) (Table 5). The score for these variables was calculated by dividing the
A risk score for prediction of MDR-TB treatment outcomes
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coefficient of the variable by 0.5 (the lowest β value, corresponding to history of taking second-
line TB treatment), multiplied by a constant (2), and rounded to the nearest integer. We
summed these points to calculate the risk score for each patient, and three risk groups were
defined: low risk (0 to 2 points), medium risk (3 to 5 points), and high risk (6 to 9 points).
Based on the risk score classification of the patients, in the derivation group, 230 (67%)
patients were assigned to the low-risk group, 89 (26%) patients to medium risk group, and 24
(7%) patients to the high-risk group. The result was similar for the validation group: 163 (72%)
patients were in the low-risk group, 46 (20%) in the medium-risk group, and 18 (8%) in the
high-risk group.
Fig 1. Flowchart of eligible participants for our study on the development of a risk score for prediction of poor
treatment outcomes among patients with multidrug-resistant tuberculosis, and reasons for exclusion.
https://doi.org/10.1371/journal.pone.0227100.g001
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Table 1. Baseline demographic and clinical characteristics of patients with multidrug resistant tuberculosis in Hunan Chest Hospital, China and University of Gon-
dar, Ethiopia, 2010–2014.
Variables Cured Treatment completed Death Treatment failure Lost to follow up Total
N = 325; n (%) N = 20; n (%) N = 18; n (%) N = 66; n (%) N = 141; n (%) N = 570; n (%)
Age < 35 years 158 (48.6) 9 (45) 5 (27.8) 23 (34.8) 49 (34.8) 244 (42.8)
Male sex 211 (64.9) 17 (85.0) 16 (88.9) 45 (68.2) 107 (75.9) 396 (69.4)
Occupation
Employed 35 (10.8) 6 (30.0) 3 (16.8) 3 (4.5) 7 (5.0) 54 (9.5)
Farmer 224 (68.9) 9 (45.0) 11 (61.1) 50 (75.8) 108 (76.6) 402 (70.5)
Unemployed 22 (6.8) 0 2 (11.1) 1 (1.52) 3 (2.13) 28 (4.9)
Daily labourer 18 (5.5) 2 (10.0) 1 (5.6) 1 (1.5) 9 (6.4) 31 (5.4)
Others 11 (3.4) 0 1 (5.6) 6 (9.1) 4 (2.8) 22 (3.9)
Unknown 15 (4.6) 3 (15) 0 5 (7.6) 10 (7.1) 33 (5.8)
Year of enrolment
2010 2 (0.6) 1 (5.0) 1 (5.6) 0 0 4 (0.7)
2011 10 (3.1) 2 (10.0) 1 (5.6) 0 0 13 (2.3)
2012 80 (24.6) 6 (30.0) 8 (44.4) 19 (28.8) 26 (18.4) 139 (24.4)
2013 107 (32.9) 9 (45.0) 4 (22.2) 31 (47.0) 43 (30.5) 194 (34.0)
2014 126 (38.8) 2 (10.0) 4 (22.2) 16 (24.2) 72 (51.1) 220 (38.6)
Study settings
Hunan Chest Hospital, China 256 (78.8) 14 (70.0) 13 (72.2) 63 (95.4) 132 (93.6) 478 (83.9)
Gondar University Hospital, Ethiopia 69 (21.2) 6 (30.0) 5 (27.8) 3 (4.6) 9 (6.4) 92 (16.1)
History of TB treatment 306 (94.1) 19 (95.0) 18 (100) 65 (98.5) 129 (91.5) 537 (94.2)
History of 2nd line TB treatment 70 (21.5) 3 (15.0) 8 (44.4) 26 (39.4) 31 (22.0) 138 (24.2)
Resistant to Ethambutol 100 (30.8) 6 (30.0) 9 (50.0) 24 (36.4) 45 (31.9) 184 (32.3)
Resistant to an injectable TB drugs 177 (54.7) 12 (60.0) 10 (55.6) 42 (63.6) 65 (46.1) 306 (53.7)
Resistant to any fluoroquinolone 17 (5.2) 0 2 (11.1) 15 (22.7) 12 (8.5) 46 (8.1)
https://doi.org/10.1371/journal.pone.0227100.t001
Table 2. The demographic and clinical characteristics of the patients by study sites (Hunan Chest Hospital, China and University of Gondar, Ethiopia), 2010–2014.






Mean (SD�) Mean (SD�) Mean (SD�)
Age (years) 38.0 ± 12.5 40.31± 2.8 32.44± 12.2
Number (%) Number (%) Number (%)
Male sex 289 (67.4) 338 (70.7) 58 (63.0)
Farmer or daily labourer 341 (79.5) 395 (82.6) 56 (60.9)
History of TB treatment 408 (95.1) 446 (93.3) 91 (98.9)
History of 2nd line TB drug treatment 107 (24.9) 137 (28.6) 1 (1.1)
Resistance to ethambutol 139 (32.4) 165 (34.5) 19 (20.6)
Resistance to any injectable TB drugs 243 (56.6) 289 (60.5) 20 (21.7)
Resistance to any fluoroquinolones 34 (7.93) 46 (9.6) 0 (0.0)
Culture did not convert at two months 158 (36.8) 122 (25.6) 65 (70.6)
Smear did not convert at two months 110 (25.6) 90 (19.1) 50 (54.3)
Derivation group 343 (60) 285 (59.6) 58 (63.0)
�SD: Standard deviation
https://doi.org/10.1371/journal.pone.0227100.t002
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In the derivation group, the proportion of patients with a poor treatment outcome was 14%
in the low-risk group, 27% in the medium-risk group, and 71% in the high-risk group. In the
validation group, the corresponding poor treatment outcome rates were 14%, 18%, and 54%,
respectively (Fig 2).
Table 3. Demographic and clinical characteristics of patients with multidrug-resistant tuberculosis in the deriva-
tion and validation groups, from Hunan Chest and Gondar University Hospitals, 2010–2014.
Risk factors Derivation (N = 227) Validation (N = 343)
Mean (SD�) Mean (SD�)
Age (years) 39.7± 13.7 38.5 ± 12.5
Number (%) Number (%)
Male sex 157 (69.2) 239 (69.7)
Farmer or daily labourer 183 (80.6) 268 (78.1)
History of TB treatment 214 (94.3) 323 (94.2)
History of 2nd line TB drug treatment 59 (25.9) 79 (23.0)
Resistance to ethambutol 83 (36.5) 101 (29.4)
Resistance to any injectable TB drugs 131 (57.7) 178 (51.9)
Resistance to any fluoroquinolones 17 (7.5) 29 (8.4)
Culture did not convert at two months 75 (33.2) 112 (32.6)
Smear did not convert at two months 54 (24.3) 86 (25.2)
�SD: Standard deviation
https://doi.org/10.1371/journal.pone.0227100.t003
Table 4. Crude hazard ratios from the univariable Cox proportional hazard model in the derivation group in
patients with multidrug-resistant tuberculosis, from Hunan Chest and Gondar University Hospitals, 2010–2014.
Risk factors Crude Hazard ratio (95% CI) P value
Mean age 1.0 (0.9–1.0) 0.81
Male sex 1.3 (0.7–2.4) 0.37
Farmer and daily labourer 0.6 (0.3–1.2) 0.15
History of TB treatment 3.3 (0.5–24.2) 0.23
History of 2nd line TB drug treatment 1.7 (1.1–3.0) 0.04
Resistance to ethambutol 1.5 (0.9–2.7) 0.11
Resistance to any injectable TB drugs 1.7 (0.9–3.0) 0.06
Resistance to any fluoroquinolones 3.1 (1.6–5.8) 0.001
Culture did not convert at two months 3.4 (1.9–5.9) 0.000
Smear did not convert at two months 2.8 (1.6–4.8) 0.000
CI: confidence interval
https://doi.org/10.1371/journal.pone.0227100.t004
Table 5. Adjusted hazard ratios, regression coefficients (β), and point score from the multivariable Cox proportional hazard model in the derivation group in
patients with multidrug-resistant tuberculosis, from Hunan Chest and Gondar University Hospitals, 2010–2014.
Risk factors Adjusted Hazard Ratio (95% CI) β-coefficient P value Points
History of second-line TB treatment 1.7 (1.1–3.2) 0.5 0.04 2
Resistance to fluoroquinolones 2.5 (1.3–4.9) 0.9 0.007 3
Smear did not convert at two months 3.0 (1.7–5.3) 1.1 <0.001 4
https://doi.org/10.1371/journal.pone.0227100.t005
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Discriminatory performance of the risk score
Discrimination measures of the derivation and validation groups are shown in Fig 3. The risk
score developed in this study had a moderate degree of accuracy to discriminate between poor
and successful treatment outcomes. The area under the ROC curve for the point system in the
derivation group was 0.69 (95% CI: 0.60 to 0.77) and was similar to that in the validation
group (0.67; 95% CI: 0.56 to 0.78; p = 0.82).
Fig 2. The proportion of patients experiencing a poor treatment outcome by clinical score in the derivation
group, the validation group and for all patients.
https://doi.org/10.1371/journal.pone.0227100.g002
Fig 3. Receiver operating characteristic curve analysis for the derivation and validation groups in patients with
multidrug-resistant tuberculosis.
https://doi.org/10.1371/journal.pone.0227100.g003
A risk score for prediction of MDR-TB treatment outcomes
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Calibration of the risk scores
The calibration of the risk score is presented graphically by plotting the observed and predicted
poor treatment outcomes. Overall, the model displayed modest calibration performance in the
derivation and validation groups (Fig 4).
Discussion
The risk score developed in this study has a moderate degree of accuracy to discriminate
between poor and successful treatment outcomes, with an AUROC score of 0.69. This discrim-
inatory performance is higher than other risk scores which have been developed for coronary
heart diseases (AUROC = 0.58–0.63) [16, 17]. However, the accuracy of the risk score in our
study is also lower than risk scores which have been developed to predict the risk of severe
dengue (0.90) [15], paediatric mortality (0.88) [18], pulmonary embolism [19] (0.85), death
from Chagas’ Heart Disease (0.81) [27], dementia (0.77) [28], and atrial fibrillation (0.78) [29].
The reason for the lower discriminatory performance in our study as compared to the studies
described above could be due to the fact that we used secondary data available from the
MDR-TB register, and as this dataset is limited, some confounding variables might be missing
and data quality might not be optimal. In contrast, previous studies developed their risk score
using primary data collected from study participants. However, developing a risk score using
routinely collected data by national TB programmes has an advantage because it might be eas-
ily applied to all patients without any additional costs.
Our study showed that clinical risk factors such as resistance to fluoroquinolone antibiotics,
history of taking second-line TB treatment, and no smear conversion at two months predicted
poor treatment outcomes in patients with MDR-TB. A risk score developed by adding points
from each of these variables classified patients into categories of low, medium and high-risk
for a poor treatment outcome with a moderate degree of accuracy. Patients in the high-risk
group could potentially benefit from intensive treatment, including psychological support,
financial assistance, and regular follow-up [30–33].
Although a clinical risk score has not been yet developed for MDR-TB, the factors that are
included in our scoring system have been identified as predictors of a poor treatment outcome
for MDR-TB patients in previous studies [34–37]. A systematic review and meta-analysis,
which was conducted to assess the impact of fluoroquinolones resistance on treatment
Fig 4. Calibration of the model using predicted and observed probabilities of poor treatment outcome for both
derivation and validation groups among patients with multidrug-resistant tuberculosis.
https://doi.org/10.1371/journal.pone.0227100.g004
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outcomes, showed that resistance to fluoroquinolones increases the risk of treatment failure,
death and relapse in patients with MDR-TB [38]. Another study conducted in Estonia showed
that history of previous TB treatment is a predictor of poor treatment outcomes in patients
with MDR-TB [37]. A study conducted in China showed that sputum smear conversion (from
positive to negative) at two months after treatment has commenced is a potential predictor of
MDR-TB treatment outcome [36].
Our study showed that resistance to fluoroquinolone antibiotics predicted poor treatment
outcomes in patients with MDR-TB. Fluoroquinolones (which included levofloxacin, moxi-
floxacin, and gatifloxacin) are broad-spectrum antibiotics and are widely used to treat several
bacterial infections [39, 40]. They are an essential component of an MDR-TB treatment regi-
men [41]. WHO recommends that fluoroquinolones are considered to be the most important
component of the core MDR-TB regimen and they should always be included unless there is
evidence for absolute contraindication for their use [42]. Resistance to fluoroquinolones,
which predominantly occurs due to prior exposure [41], continues to rise globally and is a
major clinical problem [43, 44]. The 2017 Global Tuberculosis Report reported a fluoroquino-
lone resistance rate of 20% in MDR-TB strains tested [7]. The detection of resistance to fluoro-
quinolones (using line probe assays) is included in the End-TB Strategy as part of calls for
universal access to drug susceptibility testing (DST) [45]. Tuberculosis patients with fluoro-
quinolones resistance may require regimen modification [46], such as the incorporation of
bedaquiline into the regimens [47].
Identifying groups at high risk for a poor treatment outcome, and providing appropriate
treatment would be cost-effective, especially in resource limited settings. Treatment of
MDR-TB is complex [4], and requires combinations of second-line TB drugs which are less
effective and more toxic than first-line TB drugs [2]. To increase the probability of treatment
success, high-risk patients (e.g. those with a risk score > 6 points) may require resource-inten-
sive support such as the provision of financial support, psychological counselling, and regimen
adjustment [32, 33]. Thus, our scoring system may be useful for clinicians to identify high-risk
groups in order to provide additional financial and psychosocial support for patients during
MDR-TB treatment.
This is, to our knowledge, the first published report on the development of a simple scoring
system to predict poor treatment outcomes (i.e. death, lost to follow up or treatment failure) in
patients with MDR-TB. The scoring system is based on variables that are commonly recorded
for surveillance purposes and in clinical practice. However, the study has several limitations.
First, since our study is limited by the retrospective nature of the data, some variables which
we did not include in our model might have contributed to the prediction of poor treatment
outcomes. Thus, further studies are needed to develop a scoring system which also takes into
account the potential risk factors. Second, we included all deaths occurring during the course
of treatment; however, some deaths may not have been related to MDR-TB. Third, it would be
more meaningful if we could calculate the risk score using data from one of the study hospitals
and validate this score using the data obtained from the other hospital. However, due to the
fact that we had very few data from University of Gondar Hospital, it was impractical to do
this. Thus, we preferred to merge the data and randomly divide it into derivation and valida-
tion groups. Therefore, our score system requires external validation using larger datasets and
through the use of prospective data in other settings or countries.
Conclusions
This new risk score can be used to estimate the absolute risk of poor treatment outcome in
patients with MDR-TB. Resistance to any fluoroquinolones, history of previous second-line
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TB treatment, and smear conversion status could help to identify high-risk MDR-TB patients
for poor treatment outcomes. However, our scoring system should be externally validated and
further improved to increase its predictive value.
Supporting information
S1 File. Data supporting the findings of this study.
(ZIP)
Acknowledgments
The authors would like to thank those who participated in the process of data extraction from
the medical records.
Author Contributions
Conceptualization: Kefyalew Addis Alene.
Data curation: Kefyalew Addis Alene, Zuhui Xu.
Formal analysis: Kefyalew Addis Alene.
Investigation: Kefyalew Addis Alene.
Methodology: Kefyalew Addis Alene.
Supervision: Kerri Viney, Darren J. Gray, Emma S. McBryde, Archie C. A. Clements.
Validation: Kefyalew Addis Alene.
Writing – original draft: Kefyalew Addis Alene.
Writing – review & editing: Kerri Viney, Darren J. Gray, Emma S. McBryde, Zuhui Xu,
Archie C. A. Clements.
References
1. WHO. Global tuberculosis report 2018. Geneva: World Health Organization; 2018.
2. WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resis-
tant tuberculosis. Geneva, Switzerland World Health Organization; 2014.
3. Alene KA, Clements ACA, McBryde ES, Jaramillo E, Lonnroth K, Shaweno D, et al. Mental health disor-
ders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis:
A systematic review and meta-analysis. The Journal of infection. 2018; 77(5):357–67. https://doi.org/
10.1016/j.jinf.2018.07.007 PMID: 30036607
4. WHO. Global tuberculosis report 2016. Geneva, Switzerland World Health Organization; 2016.
5. Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC. Treatment outcomes in patients with mul-
tidrug-resistant tuberculosis in north-west Ethiopia. Tropical medicine & international health. 2017;
22(3):351–62.
6. Alene KA, Yi H, Viney K, McBryde ES, Yang K, Bai L, et al. Treatment outcomes of patients with multi-
drug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis.
2017; 17(1):573. https://doi.org/10.1186/s12879-017-2662-8 PMID: 28814276
7. WHO. Global tuberculosis report 2017. Geneva: World Health Organization, 2017.
8. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-
resistant tuberculosis: a systematic review and meta-analysis. The Lancet infectious diseases. 2012;
12(6):449–56. https://doi.org/10.1016/S1473-3099(12)70033-6 PMID: 22373593
9. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes
among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. The Lancet
infectious diseases. 2009; 9(3):153–61. https://doi.org/10.1016/S1473-3099(09)70041-6 PMID:
19246019
A risk score for prediction of MDR-TB treatment outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0227100 January 3, 2020 12 / 14
10. Milanov V, Falzon D, Zamfirova M, Varleva T, Bachiyska E, Koleva A, et al. Factors associated with
treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009–2010.
International journal of mycobacteriology. 2015; 4(2):131–7. https://doi.org/10.1016/j.ijmyco.2015.03.
005 PMID: 26972881
11. Alene KA, Viney K, Gray DJ, McBryde ES, Wagnew M, Clements ACA. Mapping tuberculosis treatment
outcomes in Ethiopia. BMC Infect Dis. 2019; 19(1):474. https://doi.org/10.1186/s12879-019-4099-8
PMID: 31138129
12. Alene KA, Viney K, McBryde ES, Gray DJ, Melku M, Clements ACA. Risk factors for multidrug-resistant
tuberculosis in northwest Ethiopia: A case-control study. Transbound Emerg Dis. 2019; 66(4):1611–8.
https://doi.org/10.1111/tbed.13188 PMID: 30924283
13. Alene KA, Viney K, Yi H, McBryde ES, Yang K, Bai L, et al. Comparison of the validity of smear and cul-
ture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuber-
culosis. PLoS One. 2018; 13(5):e0197880. https://doi.org/10.1371/journal.pone.0197880 PMID:
29791488
14. WANG X-M, YIN S-H, DU J, DU M-L, WANG P-Y, Wu J, et al. Risk factors for the treatment outcome of
retreated pulmonary tuberculosis patients in China: an optimized prediction model. Epidemiology &
Infection. 2017; 145(9):1805–14.
15. Lee K, Liu J-W, Chen Y-H, Chen Y-C, Tsai C-Y, Huang S-Y, et al. Development of a simple clinical risk
score for early prediction of severe dengue in adult patients. PloS one. 2016; 11(5):e0154772. https://
doi.org/10.1371/journal.pone.0154772 PMID: 27138448
16. Chia YC, Gray SYW, Ching SM, Lim HM, Chinna K. Validation of the Framingham general cardiovascu-
lar risk score in a multiethnic Asian population: a retrospective cohort study. BMJ open. 2015; 5(5):
e007324. https://doi.org/10.1136/bmjopen-2014-007324 PMID: 25991451
17. Rodondi N, Locatelli I, Aujesky D, Butler J, Vittinghoff E, Simonsick E, et al. Framingham risk score and
alternatives for prediction of coronary heart disease in older adults. PLoS One. 2012; 7(3):e34287.
https://doi.org/10.1371/journal.pone.0034287 PMID: 22470551
18. Straney L, Clements A, Parslow RC, Pearson G, Shann F, Alexander J, et al. Paediatric index of
mortality 3: an updated model for predicting mortality in pediatric intensive care. Pediatric critical
care medicine. 2013; 14(7):673–81. https://doi.org/10.1097/PCC.0b013e31829760cf PMID:
23863821
19. Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients
with acute pulmonary embolism: a risk score. THROMBOSIS AND HAEMOSTASIS-STUTTGART-.
2000; 84(4):548–52.
20. WB. Country Income Groups (World Bank Classification), Country and Lending Groups. 2011.
21. WHO. Use of high burden country lists for tuberculosis by WHO in the post-2015 era. Geneva, Switzer-
land: 2015.
22. Biruck Kebede BA, Anteneh Kassa, Wubaye Walelgne, Andargachew Kumsa, Addisalem Yilma, Lelisa
Fekadu, Birru Shigut, Kasech Sintayehu, Solomon Hassen, Etsegenet, Endale Mengesha, Abebaw
Kebede. Guidelines on Programmatic Management of Drug Resistant Tuberculosis in Ethiopia. In:
Health FDROEMO, editor. Addis Ababa, Ethiopia 2013.
23. StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 2017.
24. WHO. Definitions and reporting framework for tuberculosis– 2013 revision (updated 2014) Geneva,
Switzerland World Health Organization 2013.
25. WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resis-
tant tuberculosis. Geneva, Switzerland 2014.
26. Sullivan LM, Massaro JM, D’Agostino RB Sr. Presentation of multivariate data for clinical use: The Fra-
mingham Study risk score functions. Statistics in medicine. 2004; 23(10):1631–60. https://doi.org/10.
1002/sim.1742 PMID: 15122742
27. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a
risk score for predicting death in Chagas’ heart disease. New England Journal of Medicine. 2006;
355(8):799–808. https://doi.org/10.1056/NEJMoa053241 PMID: 16928995
28. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the predic-
tion of dementia risk in 20 years among middle aged people: a longitudinal, population-based study.
The Lancet Neurology. 2006; 5(9):735–41. https://doi.org/10.1016/S1474-4422(06)70537-3 PMID:
16914401
29. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB Sr, et al. Development of
a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. The Lan-
cet. 2009; 373(9665):739–45.
A risk score for prediction of MDR-TB treatment outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0227100 January 3, 2020 13 / 14
30. Acha J, Sweetland A, Guerra D, Chalco K, Castillo H, Palacios E. Psychosocial support groups for
patients with multidrug-resistant tuberculosis: five years of experience. Global Public Health. 2007;
2(4):404–17. https://doi.org/10.1080/17441690701191610 PMID: 19283636
31. van Hoorn R, Jaramillo E, Collins D, Gebhard A, van den Hof S. The effects of psycho-emotional and
socio-economic support for tuberculosis patients on treatment adherence and treatment outcomes–a
systematic review and meta-analysis. PloS one. 2016; 11(4):e0154095. https://doi.org/10.1371/journal.
pone.0154095 PMID: 27123848
32. Khanal S, Elsey H, King R, Baral SC, Bhatta BR, Newell JN. Development of a Patient-Centred, Psy-
chosocial Support Intervention for Multi-Drug-Resistant Tuberculosis (MDR-TB) Care in Nepal. PloS
one. 2017; 12(1):e0167559. https://doi.org/10.1371/journal.pone.0167559 PMID: 28099475
33. Baral SC, Aryal Y, Bhattrai R, King R, Newell JN. The importance of providing counselling and financial
support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot
intervention studies. BMC public health. 2014; 14(1):46.
34. Atif M, Bashir A, Ahmad N, Fatima RK, Saba S, Scahill S. Predictors of unsuccessful interim treatment
outcomes of multidrug resistant tuberculosis patients. BMC infectious diseases. 2017; 17(1):655.
https://doi.org/10.1186/s12879-017-2746-5 PMID: 28962599
35. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant
tuberculosis: a systematic review and meta-analysis. PloS one. 2009; 4(9):e6914. https://doi.org/10.
1371/journal.pone.0006914 PMID: 19742330
36. Lv L, Li T, Xu K, Shi P, He B, Kong W, et al. Sputum bacteriology conversion and treatment outcome of
patients with multidrug-resistant tuberculosis. Infection and Drug Resistance. 2018; 11:147. https://doi.
org/10.2147/IDR.S153499 PMID: 29416359
37. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi-and extensively drug-resistant pul-
monary TB. European Respiratory Journal. 2009; 33(5):1085–94. https://doi.org/10.1183/09031936.
00155708 PMID: 19164345
38. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, et al. Resistance to fluoroquinolones and
second-line injectable drugs: impact on MDR-TB outcomes. European Respiratory Journal. 2012:
erj01347-2012.
39. Sharma PC, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and
therapeutic prospects. Acta Pol Pharm. 2009; 66(6):587–604. PMID: 20050522
40. Noel GJ. A review of levofloxacin for the treatment of bacterial infections. Clinical Medicine Therapeu-
tics. 2009; 1:CMT. S28.
41. Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis: implications in settings with
weak healthcare systems. International Journal of Infectious Diseases. 2015; 32:118–23. https://doi.
org/10.1016/j.ijid.2015.01.006 PMID: 25809767
42. WHO. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva, Switzerland:
World Health Organization; 2016.
43. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact
on bacteria, and role in evolutionary success. Trends in microbiology. 2014; 22(8):438–45. https://doi.
org/10.1016/j.tim.2014.04.007 PMID: 24842194
44. Shah NS, Wright A, Bai G-H, Barrera L, Boulahbal F, Martı́n-Casabona N, et al. Worldwide emergence
of extensively drug-resistant tuberculosis. Emerging infectious diseases. 2007; 13(3):380. https://doi.
org/10.3201/eid1303.061400 PMID: 17552090
45. WHO. End-TB strategy Geneva, Switzerland World Health Organization 2015.
46. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of
extensively drug-resistant tuberculosis. New England Journal of Medicine. 2008; 359(6):563–74.
https://doi.org/10.1056/NEJMoa0800106 PMID: 18687637
47. Organization WH. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim
policy guidance: World Health Organization; 2013.
A risk score for prediction of MDR-TB treatment outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0227100 January 3, 2020 14 / 14
